<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084563</url>
  </required_header>
  <id_info>
    <org_study_id>LMA Brasil</org_study_id>
    <secondary_id>11/1714</secondary_id>
    <nct_id>NCT02084563</nct_id>
  </id_info>
  <brief_title>Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms</brief_title>
  <official_title>Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to describe the prevalence and prognostic impact of the most
      common genetic abnormalities in patients with Myeloid Neoplasms, including Acute Myeloid
      Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndromes (MDS) and
      Myeloproliferative/Myelodysplastic Neoplasms. Patients will have samples of blood and/or bone
      marrow collected and sent to Hospital Israelita Albert Einstein for analysis and storage.

      Patients with a diagnosis of Acute Myeloid Leukemia will be treated according to an uniform
      protocol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of molecular and cytogenetic abnormalities</measure>
    <time_frame>2 years</time_frame>
    <description>As assessed by results of molecular and cytogenetic tests and frequency in the population studied</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of 5-years overall survival in patients with Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes and Myeloproliferative/Myelodysplastic Neoplasms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate complete remission (CR) rate at 1 month for patients with Acute Myeloid Leukemia who received induction chemotherapy. Complete remission was defined by the presence of &lt; 5% blasts in the bone marrow (BM) with &gt; 1 x 10^9/L neutrophils and &gt;100x10^9/L platelets in the peripheral blood (PB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate rate of 5-years disease-free survival in patients with Acute Myeloid Leukemia who enter complete remission after induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse and non-relapse mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate 5-years cumulative incidence of relapse and non-relapse mortality in patients with Acute Myeloid Leukemia who achieve complete remission following induction chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate hematological and non-hematological toxicity in patients with Acute Myeloid Leukemia treated according to the protocol. Toxicity will be graded as per the National Cancer Institute Common Toxicity Criteria for Adverse Events v4.0.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Transformation to Acute Myeloid Leukemia</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluate 5-years incidence of transformation to Acute Myeloid Leukemia in patients with Myeloproliferative Neoplasms, Myelodysplastic Syndromes and Myeloproliferative/Myelodysplastic Neoplasms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myeloproliferative Neoplasms</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative/Myelodysplastic Neoplasm</condition>
  <arm_group>
    <arm_group_label>AML-Intensive Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.
Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:
Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation
Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML-Non-intensive chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.
Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Myeloid Disorders</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with Chronic Myeloid Disorders:
Myeloproliferative Neoplasms
Myelodysplastic Syndromes
Myeloproliferative/Myelodysplastic Neoplasms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction Chemotherapy</intervention_name>
    <description>Induction chemotherapy for patients with AML eligible for intensive chemotherapy:
Cytarabine 200 mg/m2 IV continuous infusion days 1-7
Daunorubicin 90 mg/m2 intravenous piggyback days 1-3</description>
    <arm_group_label>AML-Intensive Chemotherapy</arm_group_label>
    <other_name>7+3</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Daunorubicin</other_name>
    <other_name>Anthracycline</other_name>
    <other_name>3+7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation Chemotherapy</intervention_name>
    <description>Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles</description>
    <arm_group_label>AML-Intensive Chemotherapy</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <description>Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2</description>
    <arm_group_label>AML-Intensive Chemotherapy</arm_group_label>
    <other_name>ASCT</other_name>
    <other_name>Autologous Bone Marrow Transplantation</other_name>
    <other_name>ABMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplantation</intervention_name>
    <description>Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML
Conditioning regimen:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4</description>
    <arm_group_label>AML-Intensive Chemotherapy</arm_group_label>
    <other_name>AlloSCT</other_name>
    <other_name>Allogeneic Bone Marrow Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Cytarabine</intervention_name>
    <description>Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)
Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)</description>
    <arm_group_label>AML-Non-intensive chemotherapy</arm_group_label>
    <other_name>Low dose ara-C</other_name>
    <other_name>LDAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)
Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)</description>
    <arm_group_label>AML-Non-intensive chemotherapy</arm_group_label>
    <other_name>2-aza-5Â´-deoxycytidine</other_name>
    <other_name>Dacogen</other_name>
    <other_name>DAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Acute Myeloid Leukemia-Intensive Chemotherapy

        Inclusion Criteria:

          -  Diagnosis of AML according to WHO criteria

          -  Age greater than 18 years

          -  Performance status (ECOG) between 0-2

          -  Adequate liver and kidney function

          -  Signed Informed Consent form

          -  No prior therapy for AML, except use of hydroxyurea for control of elevated white
             blood cell counts

          -  Adequate contraception for fertile men and women

          -  Eligible for intensive chemotherapy (as judged by the treating physician)

        Exclusion Criteria:

          -  Acute myeloid leukemia with retinoic acid receptor alpha (RARA) translocations (APL,
             acute promyelocytic leukemia)

          -  Pregnant women

          -  HIV-positivity

          -  New York Heart Association class III and IV congestive heart failure

          -  Patient refuses to use adequate contraception

          -  History of hypersensibility to any of the used chemotherapy drugs

          -  Patient refuses to sign informed consent form

        Acute Myeloid Leukemia-Non-Intensive Chemotherapy

        Inclusion Criteria:

          -  Diagnosis of AML according to WHO criteria

          -  Age greater than 18 years

          -  Signed Informed Consent form

          -  No prior therapy for AML, except use of hydroxyurea for control of elevated white
             blood cell counts

          -  Adequate contraception for fertile men and women

          -  Non-eligible for intensive chemotherapy (as judged by the treating physician)

        Exclusion Criteria:

          -  Acute myeloid leukemia with RARA translocations (APL, acute promyelocytic leukemia)

          -  Pregnant women

          -  HIV-positivity

          -  Patient refuses to use adequate contraception

          -  History of hypersensibility to any of the used chemotherapy drugs

          -  Patient refuses to sign informed consent form

        Chronic Myeloid Disorders:

        Inclusion Criteria:

          -  Diagnosis of Myeloproliferative Neoplasm or Myelodysplastic Syndrome or
             Myeloproliferative/Myelodysplastic Neoplasm according to WHO criteria

          -  Age greater than 18 years

          -  Signed Informed Consent form

        Exclusion Criteria:

          -  Patient refuses to sign informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio P Santos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nelson Hamerschlak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05651901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Israelita Albert Einstein</investigator_affiliation>
    <investigator_full_name>Fabio Pires de Souza Santos</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Myeloproliferative/Myelodysplastic Neoplasm</keyword>
  <keyword>Leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>MPN</keyword>
  <keyword>AML</keyword>
  <keyword>Chronic myelomonocytic leukemia (CMML)</keyword>
  <keyword>Polycythemia Vera (PV)</keyword>
  <keyword>Essential Thrombocythemia (ET)</keyword>
  <keyword>Myelofibrosis (MF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

